Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by MrMugsyon Apr 05, 2022 9:39am
153 Views
Post# 34576202

Back to ATE business ...

Back to ATE business ...As many of you have noticed, volume has trickled to almost zero.
Those who were going to leave have now done so.
That also indicates to me that those who were going to place their bets have mostly done so as well.

Sure ... a few fence sitters that are thinking about getting in/out but they don't really move the price.

Nothing really happens at this point until there is real news.

-----------------------------------

We know excitement leading up to Phase 2 will drive share price upwards eventually - waiting for that mostly during Q3 to Q4.

But in Q3, we're also going to get a glimpse of 5-ASA+H2S. 
That should also drive interest.
Looking for the chosen candidate.
Also looking for a taste of other potential candidates and the indications they might represent - as I believe this is the drug with "remarkable" anti-inflammatory properties.

That leaves an update for 352 and if that happens in Q2 ... we are then starting the domino effect of share buying sooner than later.

Just looking for that $100M valuation for ATE - that's all I'm looking for initially and then building on that for the rest of the year.

------------------------------------

That's sort of how I see it playing out.  I can absolutely live with that !

Cheers Longs !!!


<< Previous
Bullboard Posts
Next >>